This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Logan, B. Articles by Geller, N. Search for Related Content PubMed PubMed Citation Articles by Logan, B. Articles by Geller, N. Social Bookmarking                         What's this?

Use of biological assignment in hematopoietic stem cell transplantation clinical trials

Division of Biostatistics, Medical College of Wisconsin, Milwaukee, WI USA, blogan{at}mcw.edu

Eric Leifer

Office of Biostatistics Research, National Heart, Lung, and Blood Institute, National Institute of Health, Bethesda, MD, USA

Chris Bredeson

Department of Medicine, Medical College of Wisconsin, Milwaukee, WI, USA

Mary Horowitz

Center for International Blood and Marrow Transplant Research, Medical College of Wisconsin, Milwaukee, WI USA

Marian Ewell

Emmes Corporation, Rockville, MD, USA

Shelly Carter

Emmes Corporation, Rockville, MD, USA

Nancy Geller

Office of Biostatistics Research, National Heart, Lung, and Blood Institute, National Institute of Health, Bethesda, MD, USA

Background: When comparing treatments for a specific illness, it is sometimes impractical or impossible to conduct a randomized clinical trial (RCT). Biological assignment trials are one alternative design. In hematopoietic stem cell transplantation (HCT) trials, a human leukocyte antigen (HLA)-matched sibling donor is considered optimal, but such donors are available for only 20—30% of otherwise eligible patients. Rather than randomizing only those with a matched sibling donor, in a recent multiple myeloma trial, the type of HCT each patient received was biologically based, i.e., chosen according to whether or not the patient had a matched sibling donor.

Purpose: This article describes the design and implementation of biological assignment trials as well as their advantages and disadvantages.

Methods: We focus on several aspects of such trials, including efficiency of trial duration, ethical issues, and potential sources of bias. Statistical issues are considered including sample size calculations, monitoring for biased enrollment, and adjustments for imbalances in patient characteristics. A multiple myeloma trial is used as an illustration.

Results: Although they often require a larger sample size, biological assignment trials can provide substantial efficiency in terms of study duration over randomized trials when accrual to a randomized trial would be slow. Determination of sample size requires consideration of the anticipated proportion of patients with a biologically favored (HLA-matched sibling) donor. An add-on randomization of patients without a matched sibling donor may alleviate ethical concerns about applicability of study results to all patients regardless of whether the biological assignment groups differ with respect to outcome.

Limitations: Prognostic factor imbalance and enrollment bias can occur in a biological assignment trial. Statistical adjustment for potential imbalance in prognostic factors is important, as is monitoring center accrual for enrollment bias and performing an appropriate intention-to-treat analysis.

Conclusions: A biological assignment trial can be a reasonable way to compare treatments which are biologically based, such as HLA-matched sibling transplants, when the gold-standard randomized trial design is impractical or impossible. Implementing such a trial requires careful consideration of the ethical issues and potential biases.

Clinical Trials, Vol. 5, No. 6, 607-616 (2008)
DOI: 10.1177/1740774508098326


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?